These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 31415035)

  • 1. The TOMATO Study (Tacrolimus Metabolization in Kidney Transplantation): Impact of the Concentration-Dose Ratio on Death-censored Graft Survival.
    Jouve T; Fonrose X; Noble J; Janbon B; Fiard G; Malvezzi P; Stanke-Labesque F; Rostaing L
    Transplantation; 2020 Jun; 104(6):1263-1271. PubMed ID: 31415035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic concentration achievement and allograft survival comparing usage of conventional tacrolimus doses and CYP3A5 genotype-guided doses in renal transplantation patients.
    Anutrakulchai S; Pongskul C; Kritmetapak K; Limwattananon C; Vannaprasaht S
    Br J Clin Pharmacol; 2019 Sep; 85(9):1964-1973. PubMed ID: 31077425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation.
    Davis S; Gralla J; Klem P; Tong S; Wedermyer G; Freed B; Wiseman A; Cooper JE
    Am J Transplant; 2018 Apr; 18(4):907-915. PubMed ID: 28925597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation.
    Andrews LM; Hesselink DA; van Gelder T; Koch BCP; Cornelissen EAM; Brüggemann RJM; van Schaik RHN; de Wildt SN; Cransberg K; de Winter BCM
    Clin Pharmacokinet; 2018 Apr; 57(4):475-489. PubMed ID: 28681225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Effect of Inter- and Intrapatient Variability in Tacrolimus Exposure on Graft Impairment Within a 3-Year Period Following Kidney Transplantation: A Single-Center Experience.
    Stefanović NZ; Veličković-Radovanović RM; Danković KS; Mitić BP; Paunović GJ; Cvetković MB; Cvetković TP
    Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):749-760. PubMed ID: 32886348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of immunosuppressive agents and cytomegalovirus infection with de novo donor-specific antibody development within 1 year after renal transplantation.
    Fujiyama N; Satoh S; Saito M; Numakura K; Inoue T; Yamamoto R; Saito T; Nara T; Kanda S; Narita S; Kagaya H; Miura M; Habuchi T
    Int Immunopharmacol; 2019 Nov; 76():105881. PubMed ID: 31520989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
    Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Factors Affecting Tacrolimus Trough Levels in Latin American Pediatric Liver Transplant Patients.
    Riva N; Woillard JB; Distefano M; Moragas M; Dip M; Halac E; Cáceres Guido P; Licciardone N; Mangano A; Bosaleh A; de Davila MT; Schaiquevich P; Imventarza O
    Liver Transpl; 2019 Sep; 25(9):1397-1407. PubMed ID: 31102573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Interleukin-2 Receptor Antibody Induction Therapy on Survival in Renal Transplant Patients Receiving Tacrolimus.
    Ali H; Sharma A; Halawa A
    Am J Nephrol; 2020; 51(5):366-372. PubMed ID: 32268334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study.
    Gatault P; Kamar N; Büchler M; Colosio C; Bertrand D; Durrbach A; Albano L; Rivalan J; Le Meur Y; Essig M; Bouvier N; Legendre C; Moulin B; Heng AE; Weestel PF; Sayegh J; Charpentier B; Rostaing L; Thervet E; Lebranchu Y
    Am J Transplant; 2017 May; 17(5):1370-1379. PubMed ID: 27862923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
    Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation.
    Stratta P; Quaglia M; Cena T; Antoniotti R; Fenoglio R; Menegotto A; Ferrante D; Genazzani A; Terrazzino S; Magnani C
    Eur J Clin Pharmacol; 2012 May; 68(5):671-80. PubMed ID: 22101623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients.
    Seibert SR; Schladt DP; Wu B; Guan W; Dorr C; Remmel RP; Matas AJ; Mannon RB; Israni AK; Oetting WS; Jacobson PA
    Clin Transplant; 2018 Dec; 32(12):e13424. PubMed ID: 30318646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De Novo Donor-Specific Antibody Formation in Tacrolimus-Based, Mycophenolate Versus Mammalian Target of Rapamycin Immunosuppressive Regimens.
    Mithani Z; Gralla J; Adebiyi O; Klem P; Cooper JE; Wiseman AC
    Exp Clin Transplant; 2018 Feb; 16(1):23-30. PubMed ID: 28332959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal blood levels of (extended-release) tacrolimus in living donor kidney transplantation to prevent de novo donor-specific antibody production: A retrospective cohort study.
    Hiramitsu T; Tomosugi T; Futamura K; Okada M; Nishihira M; Goto N; Ichimori T; Narumi S; Kobayashi T; Uchida K; Watarai Y
    Int Immunopharmacol; 2021 Feb; 91():107038. PubMed ID: 33388731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erratic tacrolimus exposure, assessed using the standard deviation of trough blood levels, predicts chronic lung allograft dysfunction and survival.
    Gallagher HM; Sarwar G; Tse T; Sladden TM; Hii E; Yerkovich ST; Hopkins PM; Chambers DC
    J Heart Lung Transplant; 2015 Nov; 34(11):1442-8. PubMed ID: 26186804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation.
    O'Regan JA; Canney M; Connaughton DM; O'Kelly P; Williams Y; Collier G; deFreitas DG; O'Seaghdha CM; Conlon PJ
    J Nephrol; 2016 Apr; 29(2):269-276. PubMed ID: 26374111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure.
    Sapir-Pichhadze R; Wang Y; Famure O; Li Y; Kim SJ
    Kidney Int; 2014 Jun; 85(6):1404-11. PubMed ID: 24336032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Number of Episodes of Subtherapeutic Tacrolimus Blood Level Is Independently Associated With Reduced Kidney Graft Survival.
    Meisel E; Bielopolski D; Steinmetz T; Agur T; Lichtenberg S; Goldman S; Herman-Edelstein M; Nesher E; Rahamimov R; Rozen-Zvi B
    Clin Transplant; 2024 Sep; 38(9):e15460. PubMed ID: 39302223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.